Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer
NCT02568033Phase 1Unknown
- Sponsor
- Cooper University Health Care
- Start
- Oct 2013
- Primary completion
- Oct 2017
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pemetrexed, cisplatin, carboplatin, paclitaxel and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Cooper University Health Care. Primary endpoints: Disease free progression and Toxicity. Status: unknown.
02
Drugs
pemetrexedcisplatincarboplatinpaclitaxeldocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02568033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02568033.